NASDAQ:OCUL Ocular Therapeutix (OCUL) Stock Price, News & Analysis $12.30 +0.17 (+1.40%) Closing price 04:00 PM EasternExtended Trading$12.30 0.00 (0.00%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Ocular Therapeutix Stock (NASDAQ:OCUL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ocular Therapeutix alerts:Sign Up Key Stats Today's Range$12.03▼$12.4950-Day Range$8.13▼$12.6552-Week Range$5.78▼$12.91Volume1.41 million shsAverage Volume1.80 million shsMarket Capitalization$2.14 billionP/E RatioN/ADividend YieldN/APrice Target$17.20Consensus RatingBuy Company Overview Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. Read More Ocular Therapeutix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreOCUL MarketRank™: Ocular Therapeutix scored higher than 79% of companies evaluated by MarketBeat, and ranked 226th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageOcular Therapeutix has only been the subject of 3 research reports in the past 90 days.Read more about Ocular Therapeutix's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Ocular Therapeutix are expected to decrease in the coming year, from ($0.98) to ($1.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ocular Therapeutix is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ocular Therapeutix is -9.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOcular Therapeutix has a P/B Ratio of 6.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.55% of the float of Ocular Therapeutix has been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 13.31%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOcular Therapeutix does not currently pay a dividend.Dividend GrowthOcular Therapeutix does not have a long track record of dividend growth. Sustainability and ESG4.1 / 5Environmental Score-2.01 Percentage of Shares Shorted7.55% of the float of Ocular Therapeutix has been sold short.Short Interest Ratio / Days to CoverOcular Therapeutix has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Ocular Therapeutix has recently decreased by 13.31%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News SentimentN/A News SentimentOcular Therapeutix has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Ocular Therapeutix this week, compared to 5 articles on an average week.Search InterestOnly 17 people have searched for OCUL on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows3 people have added Ocular Therapeutix to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ocular Therapeutix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $208,739.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of Ocular Therapeutix is held by insiders.Percentage Held by Institutions59.21% of the stock of Ocular Therapeutix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ocular Therapeutix's insider trading history. Receive OCUL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter. Email Address OCUL Stock News HeadlinesOcular Hypertension Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future LandscapeAugust 15, 2025 | theglobeandmail.comOcular Therapeutix Earnings Call: Positive Outlook Amid Trial ProgressAugust 8, 2025 | theglobeandmail.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.August 22 at 2:00 AM | American Alternative (Ad)Analysts Have Made A Financial Statement On Ocular Therapeutix, Inc.'s (NASDAQ:OCUL) Second-Quarter ReportAugust 8, 2025 | uk.finance.yahoo.comRaymond James Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)August 6, 2025 | theglobeandmail.comOcular Therapeutix Inc (OCUL) Q2 2025: Everything You Need To Know Ahead Of EarningsAugust 6, 2025 | finance.yahoo.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | insidermonkey.comOCUL Sales Drop 18%August 5, 2025 | fool.comSee More Headlines OCUL Stock Analysis - Frequently Asked Questions How have OCUL shares performed this year? Ocular Therapeutix's stock was trading at $8.54 at the beginning of the year. Since then, OCUL shares have increased by 44.0% and is now trading at $12.30. How were Ocular Therapeutix's earnings last quarter? Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced its earnings results on Tuesday, August, 5th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. The business's revenue for the quarter was down 17.7% on a year-over-year basis. Read the conference call transcript. Who are Ocular Therapeutix's major shareholders? Top institutional shareholders of Ocular Therapeutix include Summer Road LLC (7.98%), Adage Capital Partners GP L.L.C. (2.24%), Geode Capital Management LLC (1.89%) and Deltec Asset Management LLC (1.75%). Insiders that own company stock include Summer Road Llc, Pravin Dugel, Antony C Mattessich, Sanjay Nayak, Jeffrey S Heier, Peter Kaiser, Donald Notman, Richard L Md Lindstrom, Philip C Strassburger, Christopher G White and Rabia Gurses Ozden. View institutional ownership trends. How do I buy shares of Ocular Therapeutix? Shares of OCUL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ocular Therapeutix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ocular Therapeutix investors own include Humana (HUM), Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Marinus Pharmaceuticals (MRNS) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/05/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OCUL CIK1393434 Webwww.ocutx.com Phone(781) 357-4000Fax781-357-4001Employees230Year FoundedN/APrice Target and Rating Average Price Target for Ocular Therapeutix$17.20 High Price Target$20.00 Low Price Target$15.00 Potential Upside/Downside+38.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$193.51 million Net Margins-382.51% Pretax Margin-382.51% Return on Equity-71.92% Return on Assets-49.36% Debt Debt-to-Equity Ratio0.23 Current Ratio10.10 Quick Ratio10.02 Sales & Book Value Annual Sales$56.66 million Price / Sales38.06 Cash FlowN/A Price / Cash FlowN/A Book Value$1.76 per share Price / Book7.04Miscellaneous Outstanding Shares173,995,000Free Float169,993,000Market Cap$2.16 billion OptionableOptionable Beta1.49 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OCUL) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.